CHROMOGENICS AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.38 SEK | +5.28% |
|
-5.34% | -8.86% |
| Apr. 02 | ChromoGenics AB Receives First Order for North America | CI |
| Mar. 08 | ChromoGenics AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- For several months, analysts have been revising their EPS estimates roughly upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Construction Supplies & Fixtures
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -8.86% | 3.88M | - | ||
| +18.84% | 15.13B | A+ | ||
| +14.50% | 2.57B | D+ | ||
| +19.17% | 1.15B | B | ||
| +24.62% | 823M | - | ||
| -0.28% | 405M | - | - | |
| +8.13% | 374M | - | - | |
| +6.97% | 232M | - | - | |
| +14.62% | 195M | - | - | |
| +9.72% | 168M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CHRO Stock
- Ratings ChromoGenics AB